BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 26934445)

  • 21. The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma.
    Feng X; Luo Q; Zhang H; Wang H; Chen W; Meng G; Chen F
    J Exp Clin Cancer Res; 2017 Jun; 36(1):81. PubMed ID: 28637493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tigecycline exerts an antitumoral effect in oral squamous cell carcinoma.
    Ren A; Qiu Y; Cui H; Fu G
    Oral Dis; 2015 Jul; 21(5):558-64. PubMed ID: 25581076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
    Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
    Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Silencing JARID1B suppresses oncogenicity, stemness and increases radiation sensitivity in human oral carcinoma.
    Lin CS; Lin YC; Adebayo BO; Wu A; Chen JH; Peng YJ; Cheng MF; Lee WH; Hsiao M; Chao TY; Yeh CT
    Cancer Lett; 2015 Nov; 368(1):36-45. PubMed ID: 26184998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.
    Xu WJ; Zhang S; Yang Y; Zhang N; Wang W; Liu SY; Tian HW; Dai L; Xie Q; Zhao X; Wei YQ; Deng HX
    Cancer Biother Radiopharm; 2011 Aug; 26(4):427-36. PubMed ID: 21797676
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
    Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
    Spänkuch B; Heim S; Kurunci-Csacsko E; Lindenau C; Yuan J; Kaufmann M; Strebhardt K
    Cancer Res; 2006 Jun; 66(11):5836-46. PubMed ID: 16740723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.
    Klauck PJ; Bagby SM; Capasso A; Bradshaw-Pierce EL; Selby HM; Spreafico A; Tentler JJ; Tan AC; Kim J; Arcaroli JJ; Purkey A; Messersmith WA; Kuida K; Eckhardt SG; Pitts TM
    BMC Cancer; 2018 Feb; 18(1):136. PubMed ID: 29402316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor effects of BI-D1870 on human oral squamous cell carcinoma.
    Chiu CF; Bai LY; Kapuriya N; Peng SY; Wu CY; Sargeant AM; Chen MY; Weng JR
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):237-47. PubMed ID: 24241211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RO3280: A Novel PLK1 Inhibitor, Suppressed the Proliferation of MCF-7 Breast Cancer Cells Through the Induction of Cell Cycle Arrest at G2/M Point.
    Ergul M; Bakar-Ates F
    Anticancer Agents Med Chem; 2019; 19(15):1846-1854. PubMed ID: 31244432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
    Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
    Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kochia scoparia induces apoptosis of oral cancer cells in vitro and in heterotopic tumors.
    Han HY; Lee HE; Kim HJ; Jeong SH; Kim JH; Kim H; Ryu MH
    J Ethnopharmacol; 2016 Nov; 192():431-441. PubMed ID: 27616033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiosensitization in esophageal squamous cell carcinoma: Effect of polo-like kinase 1 inhibition.
    Chen JL; Chen JP; Huang YS; Tsai YC; Tsai MH; Jaw FS; Cheng JC; Kuo SH; Shieh MJ
    Strahlenther Onkol; 2016 Apr; 192(4):260-8. PubMed ID: 26952039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of methyl 3-((2-((1-(dimethylglycyl)-5-methoxyindolin-6-yl)amino)-5-(trifluoro-methyl) pyrimidin-4-yl)amino)thiophene-2-carboxylate as a potent and selective polo-like kinase 1 (PLK1) inhibitor for combating hepatocellular carcinoma.
    Deng Z; Chen G; Liu S; Li Y; Zhong J; Zhang B; Li L; Huang H; Wang Z; Xu Q; Deng X
    Eur J Med Chem; 2020 Nov; 206():112697. PubMed ID: 32814244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased Cdc7 expression is a marker of oral squamous cell carcinoma and overexpression of Cdc7 contributes to the resistance to DNA-damaging agents.
    Cheng AN; Jiang SS; Fan CC; Lo YK; Kuo CY; Chen CH; Liu YL; Lee CC; Chen WS; Huang TS; Wang TY; Lee AY
    Cancer Lett; 2013 Sep; 337(2):218-25. PubMed ID: 23684929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The histone demethylase LSD1 is a novel oncogene and therapeutic target in oral cancer.
    Wang Y; Zhu Y; Wang Q; Hu H; Li Z; Wang D; Zhang W; Qi B; Ye J; Wu H; Jiang H; Liu L; Yang J; Cheng J
    Cancer Lett; 2016 Apr; 374(1):12-21. PubMed ID: 26872725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells.
    Pezuk JA; Brassesco MS; Ramos PMM; Scrideli CA; Tone LG
    Anticancer Agents Med Chem; 2017; 17(9):1278-1291. PubMed ID: 28270075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinoma.
    Cheung AK; Ip JC; Lung HL; Wu JZ; Tsao SW; Lung ML
    Mol Cancer Ther; 2013 Aug; 12(8):1393-401. PubMed ID: 23686835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination Treatment of Polo-Like Kinase 1 and Tankyrase-1 Inhibitors Enhances Anticancer Effect in Triple-negative Breast Cancer Cells.
    Ha GH; Kim DY; Breuer EK; Kim CK
    Anticancer Res; 2018 Mar; 38(3):1303-1310. PubMed ID: 29491053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxysophocarpine Retards the Growth and Metastasis of Oral Squamous Cell Carcinoma by Targeting the Nrf2/HO-1 Axis.
    Liu R; Peng J; Wang H; Li L; Wen X; Tan Y; Zhang L; Wan H; Chen F; Nie X
    Cell Physiol Biochem; 2018; 49(5):1717-1733. PubMed ID: 30231242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.